Search

Allma Pitru,1 Dorin Nicolae Gheorghe,2 Dora Maria Popescu,2 Flavia Mirela Nicolae,2 Mihail Virgil Boldeanu,3 Adina Turcu-Stiolica,4 Cristian Cosmin Arsenie,5 Petra Surlin,2 Sergiu Marian Cazacu,6 Ion Rogoveanu6 1Oral Pathology Department, Faculty of Dental Medicine, University of Medicine and Pharmacy of Craiova, Craiova, 200349, Romania; 2Department of Periodontology, Research Center of Periodontal-Systemic Interactions, Faculty of Dental Medicine, University of Medicine and Pharmacy of Craiova, Craiova, 200349, Romania; 3Department of Immunology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, 200349, Romania; 4Department of Pharmacoeconomics and Statistical Analysis, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, 200349, Romania; 5Doctoral School, University of Medicine and Pharmacy of Craiova, Craiova, 200349, Romania; 6Department of Gastroenterology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, 200349, RomaniaCorrespondence: Petra Surlin, Department of Periodontology, Research Center of Periodontal-Systemic Interactions, Faculty of Dental Medicine, University of Medicine and Pharmacy of Craiova, Craiova, 200349, Romania, Email surlinpetra@gmail.com Sergiu Marian Cazacu, Department of Gastroenterology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Craiova, 200349, Romania, Email sergiucazacu@umfcv.comPurpose: Non-alcoholic fatty liver disease (NAFLD) represents a heterogeneous spectrum of liver diseases that encompass simple steatosis, non-alcoholic steatohepatitis (NASH), and advanced fibrosis or cirrhosis. Periodontitis is a chronic infectious disease with multiple causal factors that presents a complex interaction between the microbial biofilm and the host’s immune response. The aim of this study was to investigate the concentrations of Vascular Adhesion Protein-1 (VAP-1) and Thrombospondin-1 (TSP-1) in patients with coexisting periodontitis

Sergiu Marian Cazacu,1,* Adina Turcu-Stiolica,2,* Dan Nicolae Florescu,1,* Bogdan Silviu Ungureanu,1,* Vlad Florin Iovanescu,1,* Carmen Daniela Neagoe,3,* Daniela Elena Burtea,1,* Amelia Valentina Genunche-Dumitrescu,3,* Taina Elena Avramescu,4,* Sevastita Iordache1,* 1Gastroenterology Department, University of Medicine and Pharmacy Craiova, Clinical Emergency Hospital Craiova, Dolj County, Romania; 2Biostatistics Department, University of Medicine and Pharmacy Craiova, Dolj County, Romania; 3Internal Medicine Department, University of Medicine and Pharmacy Craiova, Clinical Emergency Hospital Craiova, Dolj County, Romania; 4Individual Sports, and Medical Disciplines Departments, University of Craiova, Dolj County, Romania*These authors contributed equally to this workCorrespondence: Carmen Daniela Neagoe, Tel +40723767106, Email dananeagoe2014@gmail.com; daniela.neagoe@umfcv.roBackground: In upper gastrointestinal bleeding (UGIB), admissions after normal working hours and during weekends may be associated with increased mortality.Aim: To assess the evolution of the after-hours and weekend effects during the COVID-19 pandemic as a result of progressive improved management despite management challenges during the pandemic.Methods: We performed an observational study of patients admitted for UGIB at a tertiary academic center between March 2020 and December 2021, compared to the corresponding timeframe before the pandemic. Admissions were assessed based on regular hours versus after-hours and weekdays versus weekends. We stratified patients based on demographic data, etiology, prognostic scores, the time between symptom onset and admission, as and between admission and endoscopy. The outcomes included mortality, rebleeding rate, the requirement for surgery and transfusion, and hospitalization days.Results: 802 cases were recorded during the pandemic, and 1006 cases before the pande

Petrica Popa,1,* Sevastita Iordache,1,* Dan Nicolae Florescu,1,* Vlad Florin Iovanescu,1,* Alexandru Vieru,2 Valentin Barbu,2 Maria-Cristina Bezna,3,* Dragos Ovidiu Alexandru,4,* Bogdan Silviu Ungureanu,1,* Sergiu Marian Cazacu1,* 1Gastroenterology Department, University of Medicine and Pharmacy Craiova, Craiova, Dolj County, Romania; 2Gastroenterology Department, Clinical Emergency County Hospital Craiova, Craiova, Dolj County, Romania; 3Cardiology Department, Clinical Emergency County Hospital Craiova, Craiova, Romania; 4Department of Medical Informatics and Statistics, University of Medicine and Pharmacy Craiova, Craiova, Dolj County, Romania*These authors contributed equally to this workCorrespondence: Dan Nicolae Florescu, University of Medicine and Pharmacy Craiova, Gastroenterology Department, Petru Rares Street No. 2-4, Craiova, Dolj County, 200349, Romania, Tel +40723377004, Fax +40251426688, Email nicku.dan@gmail.comIntroduction: During the last few years, a progressive higher proportion of patients have had upper gastrointestinal bleeding (UGIB) related to antithrombotic therapy. The introduction of direct oral anticoagulant (DOAC) and COVID-19 pandemic may change the incidence, mortality, and follow-up, especially in patients at high risk of bleeding.Patients and Methods: We studied the use of anti-thrombotic therapy (AT) in patients with upper gastrointestinal bleeding for 5 years (January 2017–December 2021) including Covid-19 pandemic period (March 2020–December 2021). We analyzed mortality rate, rebleeding rate and need for transfusion in patients with AT therapy compared with those without AT therapy and risk factors for mortality, and also the incidence of gastrointestinal bleeding in patients admitted for COVID-19 infection.Results: A total of 824 patients were admitted during Covid-19 pandemic period and 1631 before pandemic period; a total of 426 cases of bleeding were r